Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name
This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the ...
Bausch & Lomb may be worth about $28 a share in takeover - analyst
Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...
Bausch & Lomb gains after report of PE interest in takeover
Financial writers report on private equity interest in a potential takeover of Bausch & Lomb, with firms like Blackstone and ...
Bausch + Lomb soars on report that it’s exploring a sale
A sale could value Bausch + Lomb at more than $13 billion, according to Bloomberg Intelligence analyst Mike Holland. The news is “certainly welcome to investors tied up in the Gordian’s knot at Bausch ...
Why Bausch + Lomb Rallied Today
Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care ...